GAD2/GAD65 Antibody (U.Washington patent anti-GAD65)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28688

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # U.Washington patent anti-GAD65

Concentration

LYOPH mg/ml

View all GAD2/GAD65 Antibodies »

Product Specifications

Immunogen

GAD65

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Applications for GAD2/GAD65 Antibody (U.Washington patent anti-GAD65)

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: GAD2/GAD65

Antibodies to glutamic acid decarboxylase-65 (GAD65) are present in autoimmune disorders such as insulin-dependent (type 1) diabetes mellitus (IDDM), stiff man syndrome and polyendocrine autoimmune disease. Auto-antibodies to GAD65 are present in 60-70% of individuals with newly diagnosed IDDM and thus are important markers for disease activity. These auto-antibodies usually recognize conformation-dependent regions on GAD65 and rarely bind to the second isoform, GAD67. Auto-antibodies to GAD67 are found in only 15% of recent-onset IDDM patients and most of this binding can be blocked with GAD65, suggesting shared epitopes between the two isoforms of GAD.

Long Name

Glutamate Decarboxylase 2 (Pancreatic Islets and Brain, 65kDa)

Alternate Names

GAD65

Gene Symbol

GAD2

UniProt

Q05329

Additional GAD2/GAD65 Products

Product Documents for GAD2/GAD65 Antibody (U.Washington patent anti-GAD65)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for GAD2/GAD65 Antibody (U.Washington patent anti-GAD65)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.